International Journal of Clinical Pharmacy

, Volume 33, Issue 2, pp 215–220 | Cite as

Prescribing pattern of antihypertensive drugs in a general hospital in central China

  • Hong ChengEmail author
Research Article


Objectives To examine the prescribing pattern of antihypertensive drugs in outpatients with hypertension in a general hospital in central China and identify whether the pattern of prescribing is appropriate and in accordance with national and international guidelines for pharmacotherapy of hypertension. Setting The internal medicine department of Zhongnan Hospital in central China. Method Antihypertensive prescription data were collected from the hospital’s central computer database from 1 March 2008 to 31 March 2008. Main outcome measure The most frequently used antihypertensive medications, as a percentage of treatment and of monotherapy or combination therapy. Results 1,206 prescriptions were included in the analysis. The mean age of the patient population was 61.3 ± 13.7 years and 68.6% were male. The mean number of drugs used by the patient was 1.45 ± 0.66. Of the patients, 62.9% were receiving monotherapy, 29.4% two drugs, 6.9% three drugs, and 0.8% four drugs. Most patients were receiving calcium channel blockers (58.0%), followed by angiotensin receptor blockers (34.2%), angiotensin-converting enzyme inhibitors (17.5%), beta-blockers (16.9%) and diuretics (16.7%). Conclusion This study showed that most outpatients with hypertension in our hospital received monotherapy although national and international guidelines indicated that monotherapy achieves the BP target in only a limited number of hypertensive patients. We also found that the most frequently used class of antihypertensive drugs was calcium channel blockers then angiotensin receptor blockers. Despite the various benefits of diuretics, they remain underutilized. Moreover, calcium channel blockers were used most frequently in hypertensive patients with comorbidities.


Prescribing pattern Antihypertensive drugs Hypertension China 



The author wishes to acknowledge all the doctors and pharmacists who took part in this study. The study was supported by a project from Chinese Society of Medicine Education (No. 2010-13-11).

Conflicts of interests

No conflict of interests to declare.


No financial support was received for this study.


  1. 1.
    Liu LS, Gong LS. Guidelines for the prevention and treatment of hypertension. Beiing: People’s Medical Publishing House; 2007.Google Scholar
  2. 2.
    Gu DF, Jiang H, Wu XG, Kristi R, Gan WQ, Liu DH, et al. Prevalence, awareness, treatment and control of hypertension in Chinese adults. Zhonghua Yu Fang Yi Xue Za Zhi. 2003;37(2):84–9.PubMedGoogle Scholar
  3. 3.
    Zhao XL, Chen J, Cui YL, Wu F, Hu DY. Current status of primary hypertension in China: an epidemiological study of 12 provinces, 1 autonomous regions, and 1 municipality. Chin Med J. 2006;86(16):1148–52.Google Scholar
  4. 4.
    Di Y, Hu JP, Kong LZ. Economic burden of coronary heart disease and stroke attributable to hypertension in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2006;27(9):744–7.Google Scholar
  5. 5.
    Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA. 2003;289(16):2073–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.PubMedCrossRefGoogle Scholar
  7. 7.
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–97.Google Scholar
  8. 8.
    Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354(9192):1751–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRefGoogle Scholar
  10. 10.
    British Hypertension Society. Hypertension: management of hypertension in adults in primary care. 2006.
  11. 11.
    Liu PH, Wang JD. Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res. 2008;8:133.PubMedCrossRefGoogle Scholar
  12. 12.
    Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393–404.CrossRefGoogle Scholar
  13. 13.
    Bonny A, Lacombe F, Yitemben M, Discazeaux B, Donetti J, Fahri P, et al. The 2007 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2008;26(4):825.PubMedCrossRefGoogle Scholar
  14. 14.
    Du F. Analysis of outpatient prescriptions about antihypertensive drugs. Chin Pharm Aff. 2008;22:254–6.Google Scholar
  15. 15.
    Deng BK. Use of antihypertensive drugs in the outpatients of our hospital. Eval Anal Drug-use Chin Hosp. 2007;7:350–1.Google Scholar
  16. 16.
    Cheng L, Fan JJ, Liao JP. Utilization of antihypertensive drugs in the outpatient in our hospital. Hai Jun Yi Xue Za Zhi. 2006;27:337–8.Google Scholar
  17. 17.
    Chamontin B, Poggi L, Lang T, Menard J, Chevalier H, Gallois H, et al. Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. Am J Hypertens. 1998;11(6 Pt 1):759–62.Google Scholar
  18. 18.
    Sturani A, Degli Esposti E, Serra M, Ruffo P, Valpiani G. Assessment of antihypertensive drug use in primary care in Ravenna, Italy, based on data collected in the PANDORA project. Clin Ther. 2002;24(2):249–59.PubMedCrossRefGoogle Scholar
  19. 19.
    Du WM, Wang YM, Chen BY. Utilization of antihypertensive drugs for five year in Shanghai City. Chin J Clin Pharm. 2002;11:76–8.Google Scholar
  20. 20.
    Feng L, Jiang YL, Sun CY, Dai HZ. Trends in treatment for cardiovascular diseases for three years in 22 hospitals in Nanjing City. Chin J Pharmacoepidemiol. 2004;13:22–4.Google Scholar
  21. 21.
    Liang LM, Liao GR, Li Y. Analysis of antihypertensive drugs in Guangzhou during 2001–2003. Eval Anal Drug-use Chin Hosp. 2004;4:219–21.Google Scholar
  22. 22.
    Zhao W. Investigation of application of antihypertensive drugs by four university hospitals during 2003–2004 in Beijing. Chin J Pharmacoepidemiol. 2006;15:298–300.Google Scholar
  23. 23.
    Abaci A, Kozan O, Oguz A, Sahin M, Deger N, Senocak H, et al. Prescribing pattern of antihypertensive drugs in primary care units in Turkey: results from the TURKSAHA study. Eur J Clin Pharmacol. 2007;63(4):397–402.PubMedCrossRefGoogle Scholar
  24. 24.
    Pittrow D, Kirch W, Bramlage P, Lehnert H, Hofler M, Unger T, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol. 2004;60(2):135–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Ross S, Macleod MJ. Antihypertensive drug prescribing in Grampian. Br J Clin Pharmacol. 2005;60(3):300–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Ministry of Health of China. 2008 Health statistics in China. 2008.
  27. 27.
    World Health Organization. Country health information profile. 2008.
  28. 28.
    Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of PharmacyZhongnan Hospital of Wuhan UniversityWuhanChina

Personalised recommendations